I know what you are saying and agree as that is all we have seen to this point. One of these days the market will not be able to deny the value of leronlimab.....what triggers the beginning of some valuation I’m not sure. I would think BLA submission (knowing combo approval is within 6 months), positive cancer results, and good NASH results can’t hurt either. Mono pivotal may, but if it does I think it will be because BP has to do something soon (financing vs science results).....I also expect any financing deal that gets us until revenue, license deal, up-listing, etc. are all worth some big moves also. I expect our share price has short term downside of 10-20% (over next month or so) and upside of multiple 100%s over the next few months and out 2-3 years. I’m looking forward to the ride and will buy if it happens to dip to .40c or below again.